📈 Image Fusion Restores Spatial Resolution Following Pixel‑Based Signal Averaging in Orbitrap MSI, Abstract# 328103, presented by Yury Desyaterik, Thursday June 4
📈 Development and Validation of an LC-MS/MS Method for Quantification of Protein-Unbound Doravirine in Human Plasma using Rapid Equilibrium Dialysis, Abstract# 327669, presented by Amanda Schauer, Monday June 1
Our recent work was featured as a Clinical Research Update in HIV Specialist Magazine!!
💊 Engel N, et al. Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention. J Infect Dis. 2026 Feb 18;233(2):257-260. https://t.co/bAEzrvbPyw
We supported 7 abstracts at CROI 2026!! Nathan Engel and Amanda Poliseno had great poster presentations, and our team posed with the Blue Blear in Denver, Colorado 😀
New @JIDJournal editorial favors pursuit of a clinical trial assessing on-demand #PrEP in women following our model-informed predictions of its efficacy for #HIVprevention
🔗 Editorial: https://t.co/nGRJdVxrq4
🔗 Original Publication: https://t.co/uCdyngwQqy
Our research advocating for 2-1-1-1 on-demand PrEP for cisgender women was featured in @BodyPROHIV! Check out Mackenzie Cottrell's interview with commentary from Jenell Stewart @HennepinHC discussing this "exciting step in the right direction"
🔗https://t.co/2NW1b99aag
New from our lab! Adding a 4th day to the on-demand PrEP regimen may boost HIV protection for cisgender women, according to new modeling research.
https://t.co/VYpiPHvr0C
#HIVPrevention#PrEP#WomensHealth#UNCPharmacy
🎉 Happy to share that Eli Rosen was awarded an R01!
This collaboration with OHSU will benchmark PK for both long-acting and daily ARVs in rhesus macaques and examine how pre-treatment immunopathogenic damage affects ARV tissue penetration
https://t.co/Br3Ky31lfq
#HIVResearch
Our collaboration with University of Colorado compares direct vs. indirect DBS assays for HIV PrEP adherence. We offer guidance for clinical interpretation, including adjustments for sample degradation outside cold-chain.
🔗 https://t.co/mduj0dLVM2
#HIVPrevention#PrEP
Antiretrovirals don’t reach all genital tissues equally—some areas may be underprotected. New imaging from a collaboration with our laboratory reveals why this matters for prevention and cure. #HIVresearch#ARVs#HIVprevention
https://t.co/lRSMHXdf78
New guidelines from a collaboration with our laboratory improve how we read PrEP drug levels in blood spots—helping ensure people get the protection they need. #HIVprevention#PrEP#Adherence
https://t.co/tUrDGkMhXm
The HIV PDR is revolutionizing how HIV drug data is shared—making decades of research searchable, standardized, and ready to power the next breakthroughs in treatment and prevention. #HIVresearch#DataSharing
Check out our publication here 👉 https://t.co/FCFTUEDIXw
#CROI2025 was fantastic! We are incredibly proud of Mackenzie Cottrell and her well-received oral presentation, "Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention", which is featured on NATAP!
https://t.co/a6lSKo7KWB
Check out our upcoming abstract presentation when you're at #ASCPT2025!!
A Modeling Approach to Expedite the Development of a New Long-Acting Controlled-Release Multipurpose Formulation Containing Medroxyprogesterone Acetate
📊Dose-Ranging Pharmacokinetics and Efficacy of a 90-Day Multipurpose IVR Delivering Islatravir
📊Effect of Antiretroviral Regimen on Contraceptive Failure Among Women Using Injectable Contraception